Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR1 | P47211 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 10/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14472520 | 0.91 | GALR1 (0.39) | GALR1DRD2CYP2D6DRD4DRD3 | |
| SCHEMBL14421445 | 0.91 | DRD2 (0.44) | DRD2CYP2D6DRD4DRD3 | |
| SCHEMBL14639628 | 0.90 | DRD2 (0.45) | DRD2CYP2D6DRD4DRD3 | |
| SCHEMBL5036362 | 0.89 | GALR1 (0.59) | GALR1DRD2 | |
| SCHEMBL4829406 | 0.89 | GALR1 (0.59) | GALR1DRD2 | |
| SCHEMBL4832076 | 0.89 | GALR1 (0.59) | GALR1DRD2 | |
| SCHEMBL4832720 | 0.89 | GALR1 (0.59) | GALR1DRD2 | |
| SCHEMBL4836867 | 0.89 | GALR1 (0.46) | GALR1DRD2 | |
| SCHEMBL4831978 | 0.89 | GALR1 (0.46) | GALR1DRD2CYP2D6DRD4DRD3 | |
| SCHEMBL14472443 | 0.88 | RAB9A (0.38) | GALR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GALR1 961/4885DRD2 4772/4885CYP2D6 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.